Pharmaceutical marketing: a pharma communication agency that respects the rules
Laboratories, clinical-stage biotechs, CDMOs, suppliers and e-health companies
- Medical and scientific content reviewed by your regulatory affairs
- Writers with MD and PhD backgrounds
- SEO and AI answer engine visibility
- Member of the Medicen Paris Region Partners Club
Pharmaceutical marketing is the only marketing where the law decides what you can say, to whom and in what form. Drug advertising controlled by the ANSM, regulated relations with healthcare professionals, the European regulation on medical devices, health data under GDPR: every statement commits the company. This is precisely why most laboratories and their suppliers communicate little, badly or late.
DigiObs supports pharma and healthcare companies with communication that fits this framework and stays readable: institutional and scientific communication, non-promotional information, visibility on Google and in AI engines, LinkedIn and B2B prospecting. Our MD and PhD writers write with your medical and regulatory teams, not instead of them.
Contents
Why pharmaceutical marketing has its own rules
In France, advertising for a medicine requires prior authorisation from the ANSM, and advertising to the general public is reserved for non-prescription, non-reimbursed medicines. Benefits granted to healthcare professionals are regulated and declared. Medical devices fall under European regulation 2017/745, which prohibits any misleading claim about use or performance, and some of them require advertising authorisation. Health data, finally, requires certified hosting and particular care with forms and trackers.
This framework does not make communication impossible, it shifts it: towards the company, its mission, its expertise, its research, its partnerships, its publications, and towards quality information for professionals and patients. That is where preference is built, long before any product promotion.
What we do for pharma companies
Brand platform and corporate website: positioning, messages per audience, architecture and content of a website that presents the company, its research and its expertise in compliance with advertising rules.
Medical and scientific content: articles, dossiers, summaries, information pages, written by MD and PhD profiles from the publications and reviewed by your medical and regulatory teams.
Congress communication and medical education: material, popularized abstracts, reports, LinkedIn and emailing sequences around scientific events, within the rules on relations with healthcare professionals.
SEO and GEO visibility: being found on Google and cited by ChatGPT, Perplexity and Google AI Overviews on the questions of your therapeutic area or industrial expertise, with sourced content.
LinkedIn and employer brand: editorial line, posts by the company and its executives, recruitment of scientific and industrial profiles.
B2B prospecting for pharma suppliers: CDMOs, CROs, equipment, consumables, software and services, with email and LinkedIn campaigns targeting R&D, production, quality and purchasing roles.
Does your pharma communication lack visibility, or room to manoeuvre?
Describe your activity and your constraints: we will tell you what can be said, to whom, and the plan to make it visible.
Our method in four steps
- Scope: regulatory status of each topic (medicine, device, service, institutional information), authorised audiences, internal validation circuit, mandatory mentions. This written scoping is the reference for the whole engagement.
- Position: brand platform, messages per audience (prescribers, pharmacists, hospital buyers, patients and associations, investors, candidates), evidence that can be used without promotional claims.
- Produce: content written by our scientific profiles, reviewed by your medical and regulatory affairs, published with the expected markup and mentions; visuals and material compliant with your guidelines and the applicable rules.
- Measure: Google rankings, AI citations, traffic, leads and applications in the AI Marketing Studio, with a monthly review and plan adjustment.
Who it is for
Mid-sized pharmaceutical laboratories and French subsidiaries of international groups, clinical-stage biotechs preparing their market entry, CDMOs and CROs, manufacturers of equipment and consumables, software publishers and e-health companies, pharmacy groups and healthcare providers. What they share: expert counterparts, a long decision cycle and a regulatory framework to respect at every step.
Compliance: how we work with your teams
We do not replace your regulatory affairs, we work with them. Every piece of content goes through a validation circuit defined at scoping, with a dated and archived version. We do not write claims that a publication does not support, we separate information from promotion, and we document compliance choices (mentions, audiences, consents, trackers, data hosting) for your audits. Our AI tools serve documentary research and first drafts; scientific review and validation remain human.
References in healthcare and life sciences
We support CROs, manufacturers of instruments for preclinical research, medtechs and testing laboratories. Three case studies illustrate our approach to scientific content and regulated communication.
They trust us
Many companies and institutions entrust us with their science communication, website design, campaigns and strategy.
Frequently asked questions
Can a medicine be advertised online?
In France, all advertising for a medicine requires prior authorisation from the ANSM. Advertising to the general public is only possible for non-prescription, non-reimbursed medicines; for the others, communication addresses healthcare professionals, in reserved spaces. The company website can however present the laboratory, its research and its expertise, and inform without promoting.
Can a laboratory communicate on LinkedIn?
Yes, about the company, its teams, its research, its partnerships, its publications and its events. The advertising rules for medicines and devices also apply on LinkedIn: no promotion of a product subject to authorisation outside the planned framework. A written and validated editorial line avoids improvisation.
How do AI assistants like ChatGPT handle health topics?
Carefully: they favour identified, sourced and measured material, and set aside promotional or exaggerated content. Rigorous, well-structured pharma communication is therefore naturally favoured in assistant answers, provided it exists online in a readable form. That is the purpose of our AI visibility work.
Do you work with the client's regulatory affairs?
Always. The validation circuit is defined at the start: who reviews, within what time, with what record. We prepare content ready for validation, with sources, and integrate corrections without debating the regulatory substance, which remains your responsibility.
Do you work in English and internationally?
Yes. Our writers write in French and English, and we adapt content to the rules of the target country when they differ, together with your local teams. Our clients sell in Europe, North America and Asia.
Let's talk about your project
Leading an innovative research project? Looking for a partner who can bring your idea to life beyond the scientific community?
Which type of engagement suits you best?